How much is PharmaCann worth?

Aug 16 (Reuters) - PharmaCann, one of the 10 original cannabis licensees in New York, has confidentially filed for an initial public offering that could value it at well over $1 billion, sources familiar with the matter told Reuters.

Who is PharmaCann?

PharmaCann is one of the country’s largest vertically integrated cannabis companies, providing safe, reliable, top-quality cannabis products. By investing in people, practices and infrastructure, we are shaping a new, vital, wellness-focused industry and advancing access to cannabis through effective, affordable and trusted products and services.

What happened to PharmaCann?

PharmaCann had agreed to be taken over by New York rival MedMen Enterprises Inc (MMEN.CD) in 2018 for around $700 million, but that deal fell apart the following year. (Corrects investor name in paragraph 8 to Cronos Group) Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.